comprehensive -WSS

comprehensive

author：explore 2025-08-28 08:47:04 - browse：81573

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Merck CEO won’t testify in Senate, citing no expertise in drug prices

WSS

FDA advisory panel to debate high blood pressure devices

How generative AI ratchets up security threats for health systems

How generative AI ratchets up security threats for health systems

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Listen: Vivek Ramaswamy's star turn & leaky drug data

FDA advisory panel to debate high blood pressure devices

entertainment

comprehensive

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Philips to halt sales of sleep apnea machines in U.S.

The cancer drug shortage isn’t new — and neither are the solutions

Philips to halt sales of sleep apnea machines in U.S.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Meadows told special counsel he could not recall Trump ever declassifying Mar

In Memoriam: Notable people who died in 2023

Why you shouldn’t ask, “What country has the best health care?”

Supreme Court strikes down use of affirmative action

Why Medicare shouldn’t cover every FDA

Wikipedia

Philips to halt sales of sleep apnea machines in U.S.

10 reasons why health care startups fail

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Investment in vaccine development is lagging, report finds

National associations that represent hospice owe an apology

Syphilis numbers in the United States reach record heights

focus

entertainment

focus

focus